S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
NASDAQ:PRTC

PureTech Health Stock Forecast, Price & News

$51.00
-0.58 (-1.12 %)
(As of 10/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$51.00
$51.00
50-Day Range
$44.48
$53.44
52-Week Range
$33.00
$65.90
Volume443 shs
Average Volume2,549 shs
Market Capitalization$1.46 billion
P/E Ratio2,550.00
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PRTC News and Ratings via Email

Sign-up to receive the latest news and ratings for PureTech Health and its competitors with MarketBeat's FREE daily newsletter.


PureTech Health logo

About PureTech Health

PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions. It also provides hematopoietic stem cell based therapies to treat hematological malignancies; a voice-based technology platform to measure health when a person speaks; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; Glyph, a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Roche Holding AG; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRTC
Phone
N/A
Employees
66
Year Founded
N/A

Sales & Book Value

Annual Sales
$11.77 million
Cash Flow
$0.47 per share
Book Value
$22.89 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$1.46 billion
Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.41 out of 5 stars

Medical Sector

1087th out of 1,361 stocks

Pharmaceutical Preparations Industry

523rd out of 668 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












PureTech Health (NASDAQ:PRTC) Frequently Asked Questions

Is PureTech Health a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PureTech Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PureTech Health stock.
View analyst ratings for PureTech Health
or view top-rated stocks.

What stocks does MarketBeat like better than PureTech Health?

Wall Street analysts have given PureTech Health a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but PureTech Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting PureTech Health?

PureTech Health saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 7,800 shares, an increase of 7,700.0% from the September 15th total of 100 shares. Based on an average daily volume of 3,100 shares, the days-to-cover ratio is presently 2.5 days.
View PureTech Health's Short Interest
.

What price target have analysts set for PRTC?

2 equities research analysts have issued 1-year price targets for PureTech Health's stock. Their forecasts range from $72.00 to $76.00. On average, they anticipate PureTech Health's share price to reach $74.00 in the next year. This suggests a possible upside of 45.1% from the stock's current price.
View analysts' price targets for PureTech Health
or view top-rated stocks among Wall Street analysts.

Who are PureTech Health's key executives?

PureTech Health's management team includes the following people:
  • Ms. Daphne Zohar, Founder, CEO & Exec. Director (Age 50, Pay $1.24M)
  • Dr. Bennett M. Shapiro, Co-Founder & Board Advisor (Age 81, Pay $95k)
  • Dr. Robert S. Langer Jr., Co-Founder & Non-Exec. Director (Age 72, Pay $245k)
  • Dr. Bharatt M. Chowrira, Pres, Chief of Bus. & Strategy, Sec. and Exec. Director (Age 56)
  • Dr. David R. Elmaleh, Co-Founder & Sr. Advisor (Age 73)
  • Dr. George Farmer Ph.D., Chief Financial Officer
  • Dr. Joseph B. Bolen, Chief Scientific Officer (Age 67)
  • Ms. Allison Mead Talbot, Head of Communications & Investor Relations
  • Mr. Spencer Ball, Sr. VP of HR
  • Dr. Eric Elenko, Chief Innovation Officer (Age 48)

What is PureTech Health's stock symbol?

PureTech Health trades on the NASDAQ under the ticker symbol "PRTC."

How do I buy shares of PureTech Health?

Shares of PRTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PureTech Health's stock price today?

One share of PRTC stock can currently be purchased for approximately $51.00.

How much money does PureTech Health make?

PureTech Health has a market capitalization of $1.46 billion and generates $11.77 million in revenue each year. The company earns $5.99 million in net income (profit) each year or $0.02 on an earnings per share basis.

How many employees does PureTech Health have?

PureTech Health employs 66 workers across the globe.

What is PureTech Health's official website?

The official website for PureTech Health is www.puretechhealth.com.

Where are PureTech Health's headquarters?

PureTech Health is headquartered at 6 TIDE STREET SUITE 400, BOSTON MA, 02210.

How can I contact PureTech Health?

PureTech Health's mailing address is 6 TIDE STREET SUITE 400, BOSTON MA, 02210. The company can be reached via email at [email protected].


This page was last updated on 10/18/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.